AOD 600mcg troches

AOD-9604 600 mcg Troches are a form of the peptide AOD-9604 (Advanced Obesity Drug 9604), a synthetic fragment of human growth hormone (hGH) corresponding to amino acids 176–191 with an added tyrosine for stability. It was originally developed to target fat metabolism—stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation)—while avoiding the blood-sugar effects and IGF-1 increases seen with full-length hGH. AOD-9604 has been studied in both preclinical and clinical settings. Research shows that it can enhance fat metabolism and does not significantly elevate IGF-1 or disrupt glucose homeostasis, distinguishing it from traditional growth hormone therapies. However, larger human trials have not consistently demonstrated meaningful weight loss, and development as an obesity drug was discontinued after a Phase IIb trial failed to meet primary endpoints. Troches are a sublingual (under-the-tongue) delivery form intended to allow peptide absorption without injection, though bioavailability may be lower compared with injectable routes. Products like 600 mcg troches are marketed in some peptide therapy circles for fat-loss support and metabolic modulation, but they remain research or compounding products, not FDA-approved medications. For more detailed peptide research information, see the AOD-9604 peptide profile: https://peptpedia.org/peptide/aod-9604